Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance (CROSBI ID 131821)
Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija
Podaci o odgovornosti
Brozović, Anamaria ; Osmak, Maja
engleski
Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance
Mitogen-activated protein kinases (MAPKs) are critical components of a complex intracellular signalling network that ultimately regulates gene expression in response to a variety of extracellular stimuli. By transducing the signals from the cell surface to the nucleus and activating there gene expression, MAPKs control cell proliferation, differentiation and cell death. In mammalian cells there are three major pathways of MAPKs: stress-activated protein kinase/c-Jun-N-terminal kinase (SAPK/JNK), p38 kinase and extracellular regulated kinase (ERK). Generally, SAPK/JNK and p38 are key mediators of stress and inflammation responses evoked by a variety of physical, chemical and biological stress stimuli, while ERK 1/2 cascade is mostly induced by growth factors. The importance of MAPKs activation in cell response to cis-diamminedichloroplatinum(II) (cisplatin ; cDDP) and resistance development to this anti-cancer drug has been gradually appreciated in recent years. Today it is believed that MAPK activation is a major component deciding the fate of the cell in response to cisplatin. Their role in response to cisplatin is complex as they are, in most cases, able to induce apoptosis, but also suppress it or have no role in this process, depending on cell type, and proliferation and differentiation status of tumour cells. This review summarises current knowledge concerning the role of MAPK family members in cell response to cDDP, as well as their role in cisplatin-resistance.
MAPK ; cisplatin ; drug resistance
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano